Zymeworks Inc. (ZYME) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $10.93 – $29.75
- YTD
- -11.34%
- IV Rank (30D)
- 7.43
- Straddle Price
- $4.60
- P/C Vol Ratio
- 12.96
- Market Cap
- $2.0B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $2.0B
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is al…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -5.60% | 6 |
| Feb | -3.64% | 6 |
| Mar | +0.88% | 6 |
| Apr | -4.39% | 6 |
| May | -3.01% | 6 |
| Jun | -0.15% | 5 |
| Jul | +4.18% | 5 |
| Aug | +4.72% | 5 |
| Sep | -2.72% | 5 |
| Oct | +6.24% | 5 |
| Nov | +13.70% | 5 |
| Dec | -0.10% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 35.1 | Neutral |
| MACD | 0.075 | Bullish |
| SMA 50 | $25.69 | Below |
| SMA 200 | $21.34 | Above |
| Bollinger Bands | Oversold | |
| ADX | 24.4 | Weak Trend |
| HV 30 | 48.3% |
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Published | Title | Publisher | Sentiment |
|---|---|---|---|
| 2026-04-17 | Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform | GlobeNewswire Inc. | |
| 2026-04-09 | Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth | GlobeNewswire Inc. | |
| 2026-04-01 | Zymeworks Appoints Kristin Stafford as Chief Financial Officer | GlobeNewswire Inc. | |
| 2026-03-30 | Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate | GlobeNewswire Inc. | |
| 2026-03-24 | Zymeworks Announces Participation in Upcoming Investor Conferences | GlobeNewswire Inc. | |
| 2026-02-12 | Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 | GlobeNewswire Inc. | |
| 2026-01-27 | Zymeworks Announces Participation in Upcoming Investor Conferences | GlobeNewswire Inc. | |
| 2026-01-07 | Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial | Benzinga |
- IV Rank (30D)
- 7.43
- IV Rank (7D)
- 51.93
- Avg IV
- 78.5%
- Straddle (30D)
- $4.60
- Straddle (7D)
- $2.77
- P/C Volume
- 12.96
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.90
- Correlation (SPY)
- 20.8%
- R²
- 0.04
- Ann. Volatility
- 54.0%
- SPY Volatility
- 12.5%
Moderate volatility - stock generally follows market
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 7.4 |
| P/S Ratio | 18.6 |
| EV/EBITDA | -22.8 |
| ROE | -30.2% |